This study clearly showed that activation of the caspase-11 non-canonical inflammasome and GSDMD is a key event in SLE pathology in two lupus mouse models, and that selective inhibition of these two molecules is a possible therapeutic approach to treat SLE. Here, GSDMD is linked to systemic lupus erythematosus.